Interview with CEO Tony Paré and CFO Niel Goldman - Full Year 2022 report
Interview with CEO Tony Paré and CFO Niel Goldman - Full Year 2022 report
Bioporto received an AI letter from FDA, which is a standard procedure and nothing to worry about. CEO Tony Paré seems very confident about the process and expect to deliver on the deadline end June 2023. While they wait for the outcome from FDA, they turn their focus on Europe where they have a CE-approval of NGAL.
CFO Niel Goldman gave a detailed explanation of the 2022 numbers. They expect better sales and lower ebitda loss for 2023.
Please listen here: https://www.inderes.dk/videos/bioporto-presentation-of-annual-report-2022
Disclaimer:
HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 3:00 PM 03-31-2023.